Company Leadership

Meg Powell, Pharm.D.
CEO, President, and Co-Founder

Dr. Powell has over 15 years of experience in the pharmaceutical industry including assignments at McKinsey, Eli Lilly and GlaxoSmithKline. Currently she is serving as CEO of TARGET PharmaSolutions.

She has worked with multiple start-up companies while at Medgility, a consulting firm focused on Strategy and Business Development of Emerging Companies.  These include Qura Therapeutics, KemPharm, Inc, and most notably, Aerial Biopharma where she was the Interim VP of Corporate Development and was instrumental in the sale of ADX-N05 to Jazz Pharmaceuticals.

Prior to her work at Medgility, Dr. Powell was Vice President of the US Transformation Office at GlaxoSmithKline. She has in depth experience in sales and marketing for US and Global development programs at all stages – from Phase 1 to post patent expiry.

Dr. Powell received her Doctorate of Pharmacy degree from the University of North Carolina- Chapel Hill where she was a Hollingsworth Scholar.  She also received a Master’s of Business Administration from Stanford University.

George Demuth
Vice President, Data Management And Statistical Reporting

Mr. DeMuth has over 25 years of experience working as a lead statistician on clinical trials in support of pharmaceutical, medical device, and biologic products. He previously owned and operated a clinical research organization (CRO) for 17 years. Mr. DeMuth has worked with several hundred companies across numerous therapeutic areas and supported many approved products. He has attended numerous FDA meetings as the client’s representative and has presented at FDA panel meetings. Mr. DeMuth has extensive programming experience and has developed several statistical reporting packages using SAS macros. He has also developed Stat One EDM TM, an electronic data capture system.

Elizabeth L. Moore, MS RAC
Vice President, Clinical Operations

Elizabeth Moore, MS, RAC brings to Target PharmaSolutions over 30 years of experience in drug development including clinical, regulatory, and training positions in pharmaceutical companies and contract research organizations. She has managed clinical and regulatory teams on US and global projects in a variety of therapeutic areas including neurology and cardiovascular medicine.

Weston Fox
Vice President, Corporate Development

Weston is currently serving as Vice President, Corporate Development for TARGET PharmaSolutions.

Prior to joining TARGET, Weston was a Director at Novartis in their Global Development organization.  Prior to Novartis, Weston worked for a number of years at Quintiles in a variety of positions, including Corporate Development, Business Development and Operations.  His most recent position at Quintiles was Executive Director, Global Sales where he was responsible for Quintiles’ global Business Development activities for two enterprise accounts.  Weston also previously worked for The Boston Consulting Group and Carousel Capital, a mid-market focused private equity firm.

Weston received his MBA from the Kenan-Flagler Business School at the University of North Carolina and his BA from the University of Virginia where he was a Jefferson Scholar.

David Nelson, MD
Scientific Advisor And Co-Founder

Dr. David Nelson is Professor of Medicine and Assistant Vice President for Research at the University of Florida where he serves as the Director of the Clinical and Translational Science Institute. At this position he focuses on improving how biomedical research is conducted and how to enable scientists to collaborate more efficiently in order to accelerate the translation of laboratory discoveries into real- world clinical treatments.

Dr. Nelson’s area of clinical expertise is Hepatology with an emphasis on the management of viral hepatitis and liver cancer. He has strong translational research interests, focusing primarily on the immunopathogenesis and treatment of chronic hepatitis C and hepatocellular carcinoma.  In 2013, he was recognized as one of the Clinical Research Forum’s Top 10 Clinical Research Achievements and in 2014 received the AAMC Learning Health System Champion Research Award. He currently oversees more than 15 active clinical trials and has a 15 year track record of NIH funding. . Dr. Nelson has an impressive record of academic achievement with more than $40 million in research funding and over 200 publications.

He received his undergraduate degree from Dartmouth College, his medical degree from SUNY Upstate University in Syracuse, completed a Residency in Internal Medicine at The University of Massachusetts, and obtained fellowship training in Gastroenterology and Hepatology at the University of Florida.

Joy Peter
Operations Advisor and Co-Founder

Joy Peter is the Associate Director of Hepatology Research at the University of Florida in Gainesville, FL where she oversees the clinical, fiscal, and regulatory operations of a very active liver research program of more than 30 active studies with annual revenue of $2.0M.

She is also the Associate Director for the Hepatitis C Therapeutic Registry and Research Network (HCV-TARGET), a large international network of more than 50 academic and community investigators partnered with the FDA and HCV patient advocacy groups.

Her primary clinical and research interest is HCV. She was a key member in developing the HCV-TARGET network and study processes generating more than $27M in funding over 4 years. She is a contributing author on publications in hepatitis-C, PBC, and NASH and has been an invited speaker on HCV for both non-profit and industry-sponsored programs.  She is a member of AASLD and EASL and has served on the AASLD Education Committee and Education Oversight Committee. Additionally, she has Chaired the Associates Committee from 2011-2013 and currently Chairs the Mid-level Professionals Abstract Review Panel.

Joy earned her Bachelor of Science in Nursing from California State University at Hayward and began her career in Hepatology at Emory University in Atlanta.

Michael W. Fried, MD
Scientific Advisor and Co-Founder

Michael W. Fried, MD is Professor of Medicine and Director of Hepatology at the University of North Carolina at Chapel Hill.  Dr. Fried completed his internship and residency in internal medicine at the State University of New York (SUNY) Health Science Center at Syracuse, where he also completed a fellowship in gastroenterology.

From 1990 to 1993, while serving as Medical Staff Fellow in the Liver Diseases Section at the National Institutes of Health (NIH) in Bethesda, Maryland, Dr. Fried performed clinical and laboratory studies of viral hepatitis.  During his tenure at UNC, he has been the principal investigator on numerous phase I, II, and III clinical trials of antiviral agents for chronic hepatitis B and hepatitis C.  Dr. Fried has been awarded continuous NIH extramural funding for more than 15 years as principal investigator on multiple NIH cooperative clinical trials, including as current co-Chair of the Hepatitis B Research Network (NIDDK).

Dr. Fried is the recipient of an NIH career development award, which allows him to provide mentorship to junior investigators in hepatitis research.  Most recently, Dr. Fried is co-principal investigator of the HCV-TARGET international network of investigators to study the real-world experience with therapies for hepatitis C.

Dr. Fried is the primary author or co-author on over 140 original publications, reviews, and book chapters concentrated in the field of viral hepatitis.  His manuscript on therapy of HCV, published in 2002, established the standard of care for this disease for more than a decade and was one of the most highly cited publications in the field of gastroenterology.

Dr. Fried was inducted into the American Society of Clinical Investigation (ASCI), an honor society for clinical investigators.  Dr. Fried was recently elected to the Governing Board of the American Association for the Study of Liver Diseases (AASLD) and will assume the role of President of AASLD in 2019.

Jeffrey K. Giguere, MD
Board Observer

Dr. Giguere is currently a practicing Oncologist and Principal Investigator at Greenville Health Systems Cancer Institute in Greenville, South Carolina. He has held the position of Principal Investigator since 1995 where he has overseen its dramatic expansion. Additionally Dr. Giguere has served as President of the South Carolina Oncology Society. He has received various awards for his work including honors from the American Board of Internal Medicine, the National Board of Medical Examiners and the prestigious Gen. Graves Ersike Award for Outstanding Fellow at Walter Reed Army Medical Center.

He is also active in the Greenville, SC community where he sits on the board of a philanthropy committee of a $4.8 million park dedicated to Cancer Survivors.

Dr. Giguere holds a BS and MD from Duke University and completed his residency at Vanderbilt University. He also served in the United State Air Force as a practicing physician at both USAF Hospital in Plattsburgh, NY and at Walter Reed Army Medical Center in Washington, DC.

Bobby Helmedag
Board Member

Bobby manages the operations of Rex Health Ventures, a corporate venture fund backed by UNC Rex Healthcare in Raleigh, NC.  Since its launch in 2012, Rex Health Ventures has invested in 8 portfolio companies across several areas of healthcare including medical devices, healthcare services, diagnostics, technology enabled services and drug development.  Bobby is responsible for deal sourcing, due diligence and portfolio management.

Prior to Rex Health Ventures he worked at Blue Cross Blue Shield of Tennessee in corporate development.

He has an International MBA from the University of South Carolina and a Bachelor’s of Finance from the University of Notre Dame.

Moise A. Khayrallah, PhD
Board Chairman

Dr. Khayrallah has been involved in drug development for over 28 years in executive as well as research and development positions having acquired his experience in diverse pharmaceutical environments including large pharmaceutical, contract research, and biotechnology companies. Currently he is Chairman of the Board and co-Founder of QuatroBio, LLC, a biopharmaceutical holding company focused on developing drugs for central nervous system disorders. He has extensive experience in the entrepreneurial space having lead multiple healthcare companies including Aerial Biopharma, Neruronex Inc, and Addrenex Pharmaceuticals.

Additionally Dr. Khayrallah is actively involved in philanthropic, entrepreneurial and social networks in North Carolina. In 2014 he endowed the Moise A. Khayrallah Center for Lebanese Diaspora Studies at North Carolina State University, the first center of its kind outside of Lebanon. The Center is the first endowed center in NC State’s history and the largest gift to the College of Humanities and Social Sciences. He is also Chairman of the Board of the UNC Center for International Understanding where he works with the Center on enhancing North Carolina’s global engagement. Additionally Dr. Khayrallah is highly involved in the North Carolina Ballet at his position of Chairman of the Board.

Dr. Khayrallah holds a Ph.D. degree in Psychology from the University of North Carolina at Chapel Hill and a Bachelor’s degree in Psychology from the American University of Beirut.

Meg Powell, Pharm.D.
CEO, President, and Co-Founder

Dr. Powell has over 15 years of experience in the pharmaceutical industry including assignments at McKinsey, Eli Lilly and GlaxoSmithKline. Currently she is serving as CEO of TARGET PharmaSolutions.

She has worked with multiple start-up companies while at Medgility, a consulting firm focused on Strategy and Business Development of Emerging Companies.  These include Qura Therapeutics, KemPharm, Inc, and most notably, Aerial Biopharma where she was the Interim VP of Corporate Development and was instrumental in the sale of ADX-N05 to Jazz Pharmaceuticals.

Prior to her work at Medgility, Dr. Powell was Vice President of the US Transformation Office at GlaxoSmithKline. She has in depth experience in sales and marketing for US and Global development programs at all stages – from Phase 1 to post patent expiry.

Dr. Powell received her Doctorate of Pharmacy degree from the University of North Carolina- Chapel Hill where she was a Hollingsworth Scholar.  She also received a Master’s of Business Administration from Stanford University.